On basis of network pharmacology and molecular docking technology, discussing mechanism and application of shrub althea flower-astragalus membranaceus compatibility in prevention and treatment of diabetic cardiomyopathy

Abstract

The invention discusses a mechanism for preventing and treating diabetic cardiomyopathy through shrub althea flower-astragalus membranaceus compatibility based on network pharmacology and a molecular docking technology and application, and belongs to the field of biological medicine. The method comprises the following steps: firstly, collecting shrubalthea flower and astragalus membranaceus components by utilizing HERB and TCMSP databases respectively, screening active components by utilizing a SwisADME platform, and obtaining active component action targets by utilizing a SwisTar getPrediction tool; the method comprises the following steps: retrieving a diabetic cardiomyopathy action target spot by utilizing a GeneCards database, an OMIM database and a DygBank database; and drawing a Wehn diagram to display an intersection target of the medicine and the disease. Secondly, constructing a protein interaction network by utilizing an STRING database, screening core targets by utilizing Cytoscape software, and constructing a'traditional Chinese medicine-component-disease-target 'network; and finally, carrying out GO and KEGG enrichment analysis by utilizing a Metascap database, and carrying out molecular docking by utilizing AutoDockTools software. The invention verifies that the novel traditional Chinese medicine compound shrub althea flower-astragalus membranaceus can prevent and treat diabetic cardiomyopathy through multiple components, multiple targets and multiple paths, and 8 '-epiday lily lignan A and quercetin are expected to become effective components for research and development of drugs for treating diabetic cardiomyopathy.

Images